A trial looking at ZD4054 for prostate cancer that has spread to the bones

Cancer type:

Prostate cancer




Phase 2

This trial compared different doses of a new drug called ZD4054 for prostate cancer that had spread to the bones.

Doctors usually treat prostate cancer with surgery, radiotherapy or hormone therapy. But sometimes the cancer continues to grow, and when this happens it can be more difficult to treat.

Endothelin 1 (ET1) is a growth factor made by the body. It attaches to receptors on prostate cancer cells called endothelin A receptors. When ET1 binds to the receptor, it encourages the cell to grow and divide.

ZD4054 is a new type of biological therapy. It is called an ‘endothelin A receptor antagonist’. This means it stops ET1 attaching to the endothelin A receptor. Doctors hoped that if the ET1 could not attach to the receptor, it would not be able to tell the cell to grow and divide. But they were not sure how well it would work.

The aim of this trial was to find out how well ZD4054 worked for prostate cancer that had spread to the bones. And to find out more about the side effects of ZD4054.

Summary of results

The trial team found that overall ZD4054 did help men to live longer with prostate cancer that had spread.

This trial recruited 312 men. It was a randomised trial. The men were put in to 1 of 3 treatment groups by a computer. Neither the men nor their doctor knew which group they were in. This is called a double blind trial.

In group 1, 107 men had ZD4054.

In group 2, 98 men had a higher dose of ZD4054.

In group 3, 107 men had a dummy drug (placebo).

The average time it took for the cancer to start growing again was

  • 4 months for men in group 1
  • Just under 4 months for men in group 2
  • Just over 3½ months for men in group 3

Overall the average amount of time the men in each group lived for was

  • 24½ months in group 1
  • 23½ months in group 2
  • Just under 17½ months in group 3

The main side effects reported were

After doing another trial the researchers decided not to develop ZD4054 further.

We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) and published in a medical journal. The figures we quote above were provided by the trial team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor Nick James

Supported by


Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

Oracle 524

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Keith took part in a trial looking into hormone therapy

A picture of Keith

"Health wise I am feeling great. I am a big supporter of trials - it allows new treatments and drugs to be brought in.”

Last reviewed:

Rate this page:

No votes yet
Thank you!
We've recently made some changes to the site, tell us what you think

Share this page